Ferulic acid (Synonyms: Coniferic acid)

Name: Ferulic acid
Brand: MedChemExpress
SKU: HY-N0060
Rating: 5.0 (16 reviews)

Cat. No.: HY-N0060 Purity: 99.97%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Ferulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC₅₀s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively.

For research use only. We do not sell to patients.

CAS No. : 1135-24-6

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
100 mg	In-stock	Estimated Time of Arrival: December 31
1 g	In-stock	Estimated Time of Arrival: December 31
5 g	In-stock	Estimated Time of Arrival: December 31
10 g	Get quote
50 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 16 publication(s) in Google Scholar

Other Forms of Ferulic acid:

16 Publications Citing Use of MCE Ferulic acid

Cell Proliferation/Viability Assay

Bio/Physico-chemical Assay

Histological Imaging/Staining

ELISA

: Ferulic acid purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 May:140:156573. [Abstract]; HPLC chromatogram of Ferulic Acid.

: Ferulic acid purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 May:140:156573. [Abstract]; Ferulic Acid (FA, 100 μM; 4 h) effectively inhibited LPS-induced upregulation of E-selectin, VCAM-1, TF and PAI-1 in HUVEC.

: Ferulic acid purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2025 Aug 13:240:183-196. [Abstract]; Effects of different concentrations of Ferulic acid (FA, 10, 50, 200, 500 μg/mL) and/or Dex (20 μM) continuously treated for 48 h on the proliferative vigor of C2C12 cells (CCK-8 assay). The results showed that compared with dexamethasone (Dex) treatment, FA (1–50 μg/mL; 48 h) treatment tended to promote the proliferative activity of C2C12 cells. Furthermore, FA (50 μg/mL) significantly reversed the decrease in proliferative activity of C2C12 cells induced by Dex treatment.

: Ferulic acid purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2025 Aug 13:240:183-196. [Abstract]; Myotube(dark blue) morphology of each group after 72 h of treatment with Gimsa staining. Gimsa staining showed that the diameter and number of myotube decreased after Dexamethasone (Dex) treatment and recovered after Ferulic acid (FA, 10-200 μg/mL; 72 h) intervention.

: Ferulic acid purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2025 Aug 13:240:183-196. [Abstract]; Effects of different concentrations of Ferulic acid (FA,10, 50, 200 μg/ml) and/or Dexamethasone (Dex, 20 μM) on the levels of inflammatory factors TNF-α, IL-6 in the supernatant of C2C12 cell culture after 72 h of continuous treatment. The results showed that FA (10–200 μg/mL) could reduce the levels of TNF-α and IL-6 in the Dex group, with the effects being more significant at concentrations of 50 μg/mL and 200 μg/mL, indicating that FA inhibits sarcopenia-associated inflammation.

: Ferulic acid purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2025 Aug 13:240:183-196. [Abstract]; Immunofluorescence technique was used to detect the expression of ACOX1 at different concentrations of Ferulic acid (FA) (50, 200 μg/ml) and/or Dexamethasone (Dex) (20 μM) after 72 h of continuous treatment (200 × ). NC: Normal Control group; Dex: Model group; FA: Model + FA group. Immunofluorescence assay showed that ACOX1 was significantly reduced after Ferulic acid (FA) (200 μg/mL) intervention compared with the Dex group.

: Ferulic acid purchased from MedChemExpress. Usage Cited in: Neurotherapeutics. 2023 Jul;20(4):1081-1108. [Abstract]; Ferulic acid (FA; 5, 10 μM; 2 h) restores the Aβ-induced decreased expression of p-Y416 and increased expression of npS221 in neuronal cells.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Endogenous Metabolite Isoform Specific Products:

View All Isoforms

Human Endogenous Metabolite Microbial Metabolite

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

Ferulic acid is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC₅₀s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively.

IC₅₀ & Target^[1]

FGFR1

3.78 μM (IC₅₀)

FGFR2

12.5 μM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	2.6 mM Compound: Ferulic acid	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by FMCA assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by FMCA assay	[PMID: 27162124]
A549	IC₅₀	3.1 mM Compound: Ferulic acid	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 27162124]
A549	IC₅₀	3.2 mM Compound: Ferulic acid	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by luminescence-based ATP assay Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 48 hrs by luminescence-based ATP assay	[PMID: 27162124]
A549	IC₅₀	> 10 μM Compound: 7	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 27700070]
A549	IC₅₀	> 100 μM Compound: 13	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 21696954]
BT-549	IC₅₀	1.2 μM Compound: 1	Antiproliferative activity against human BT549 cells after 24 hrs by MTT assay Antiproliferative activity against human BT549 cells after 24 hrs by MTT assay	[PMID: 29144746]
BT-549	IC₅₀	> 10 μM Compound: 7	Cytotoxicity against human BT549 cells after 48 hrs by SRB assay Cytotoxicity against human BT549 cells after 48 hrs by SRB assay	[PMID: 27700070]
BV-2	EC₅₀	> 10 μM Compound: 2	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced microglial activation after 24 hrs by Griess reagent based assay Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced microglial activation after 24 hrs by Griess reagent based assay	[PMID: 29407994]
BV-2	IC₅₀	> 50 μM Compound: 7	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 27700070]
C2BBe1	IC₅₀	> 200 μM Compound: 2; FA	Cytotoxicity against human C2BBe1 cells assessed as reduction in cell proliferation after 24 hrs by sulforhodamine B assay Cytotoxicity against human C2BBe1 cells assessed as reduction in cell proliferation after 24 hrs by sulforhodamine B assay	[PMID: 27290693]
C2BBe1	IC₅₀	> 200 μM Compound: 2; FA	Cytotoxicity against human C2BBe1 cells assessed as reduction in cell proliferation after 48 hrs by sulforhodamine B assay Cytotoxicity against human C2BBe1 cells assessed as reduction in cell proliferation after 48 hrs by sulforhodamine B assay	[PMID: 27290693]
C2BBe1	IC₅₀	> 200 μM Compound: 2; FA	Cytotoxicity against human C2BBe1 cells assessed as reduction in cell proliferation after 72 hrs by sulforhodamine B assay Cytotoxicity against human C2BBe1 cells assessed as reduction in cell proliferation after 72 hrs by sulforhodamine B assay	[PMID: 27290693]
C2BBe1	IC₅₀	> 200 μM Compound: 2; FA	Cytotoxicity against human C2BBe1 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay Cytotoxicity against human C2BBe1 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay	[PMID: 27290693]
HT-22	EC₅₀	> 10 μM Compound: 2	Neuroprotective activity against IAA-induced ischemia in mouse HT22 cells assessed as increase in cell viability cotreated with IAA for 2 hrs followed by IAA wash out measured after 24 hrs by MTT assay Neuroprotective activity against IAA-induced ischemia in mouse HT22 cells assessed as increase in cell viability cotreated with IAA for 2 hrs followed by IAA wash out measured after 24 hrs by MTT assay	[PMID: 29407994]
K562	IC₅₀	> 1000 μM Compound: Ferulic acid	Cytotoxicity against human K562 cells after 5 days by XTT assay Cytotoxicity against human K562 cells after 5 days by XTT assay	[PMID: 18076140]
LoVo	IC₅₀	95 μM Compound: 13	Cytotoxicity against human LoVo cells after 72 hrs by MTT assay Cytotoxicity against human LoVo cells after 72 hrs by MTT assay	[PMID: 21696954]
MCF7	IC₅₀	0.36 μM Compound: FerA	Antiproliferative activity against human MCF7 cells assessed as cell viability after 24 hrs Antiproliferative activity against human MCF7 cells assessed as cell viability after 24 hrs	[PMID: 33139111]
MDA-MB-231	IC₅₀	0.5 μM Compound: 1	Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 29144746]
MDA-MB-231	IC₅₀	15 μM Compound: FerA	Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs	[PMID: 33139111]
MT4	CC₅₀	> 10 μM Compound: 8	Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by CytoTox-Glo assay Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 3 days by CytoTox-Glo assay	[PMID: 26756779]
MT4	EC₅₀	> 10 μM Compound: 8	Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in viral replication measured on day 3 post infection by luciferase reporter gene assay Antiviral activity against HIV1 NL4-3 infected in human MT4 cells assessed as reduction in viral replication measured on day 3 post infection by luciferase reporter gene assay	[PMID: 26756779]
Neutrophil	IC₅₀	200 μM Compound: 2; FA	Inhibition of phorbol myristate acetate-induced human neutrophils oxidative burst assessed as reduction in luminol oxidation preincubated for 5 mins followed by PMA addition measured after 15 mins by chemiluminescence assay Inhibition of phorbol myristate acetate-induced human neutrophils oxidative burst assessed as reduction in luminol oxidation preincubated for 5 mins followed by PMA addition measured after 15 mins by chemiluminescence assay	[PMID: 27290693]
PC-3	IC₅₀	> 100 μM Compound: 13	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 21696954]
Platelet	IC₅₀	19.58 mM Compound: Ferulic acid	Antiplatelet aggregation activity in rabbit platelet assessed as reduction in ADP-induced platelet aggregation Antiplatelet aggregation activity in rabbit platelet assessed as reduction in ADP-induced platelet aggregation	[PMID: 34902735]
Platelet	IC₅₀	2.7 mM Compound: Ferulic acid	Inhibition of ADP-induced rabbit platelet aggregation compound pre-incubated in rabbit liver microsomal suspension Inhibition of ADP-induced rabbit platelet aggregation compound pre-incubated in rabbit liver microsomal suspension	[PMID: 23466230]
RAW264.7	IC₅₀	> 100 μM Compound: 12	Antiinflammatory activity in mouse RAW264.7 cells assessed as decrease in LPS-induced NO production after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as decrease in LPS-induced NO production after 24 hrs by Griess assay	[PMID: 25666824]
SH-SY5Y	IC₅₀	11.82 μM Compound: ferulic acid	Antioxidant activity in human SH-SY5Y cells assessed as reduction in H2O2-induced reactive oxygen species formation measured after 24 hrs by DCFH-DA probe based fluorescence assay Antioxidant activity in human SH-SY5Y cells assessed as reduction in H2O2-induced reactive oxygen species formation measured after 24 hrs by DCFH-DA probe based fluorescence assay	[PMID: 28282613]
SK-MEL-2	IC₅₀	> 10 μM Compound: 7	Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay	[PMID: 27700070]
SK-MEL-28	IC₅₀	> 100 μM Compound: 13	Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay	[PMID: 21696954]
SK-OV-3	IC₅₀	> 10 μM Compound: 7	Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay	[PMID: 27700070]
TT	IC₅₀	150 μM Compound: Ferulic acid	Cytotoxicity against human TT cells by trypan blue dye-based assay Cytotoxicity against human TT cells by trypan blue dye-based assay	[PMID: 31336310]
U-373MG ATCC	IC₅₀	> 100 μM Compound: 13	Cytotoxicity against human U373 cells after 72 hrs by MTT assay Cytotoxicity against human U373 cells after 72 hrs by MTT assay	[PMID: 21696954]
WiDr	IC₅₀	> 200 μM Compound: 2; FA	Cytotoxicity against human WiDr cells assessed as reduction in cell proliferation after 24 hrs by sulforhodamine B assay Cytotoxicity against human WiDr cells assessed as reduction in cell proliferation after 24 hrs by sulforhodamine B assay	[PMID: 27290693]
WiDr	IC₅₀	> 200 μM Compound: 2; FA	Cytotoxicity against human WiDr cells assessed as reduction in cell proliferation after 48 hrs by sulforhodamine B assay Cytotoxicity against human WiDr cells assessed as reduction in cell proliferation after 48 hrs by sulforhodamine B assay	[PMID: 27290693]
WiDr	IC₅₀	> 200 μM Compound: 2; FA	Cytotoxicity against human WiDr cells assessed as reduction in cell proliferation after 72 hrs by sulforhodamine B assay Cytotoxicity against human WiDr cells assessed as reduction in cell proliferation after 72 hrs by sulforhodamine B assay	[PMID: 27290693]
WiDr	IC₅₀	> 200 μM Compound: 2; FA	Cytotoxicity against human WiDr cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay Cytotoxicity against human WiDr cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay	[PMID: 27290693]

In Vitro

Ferulic acid (FA) is a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor with IC₅₀s of 3.78 and 12.5 μM for FGFR1 and FGFR2, respectively. Ferulic acid exhibits great inhibitory activity on FGFR1 with an inhibitory rate of 92% at 1 μM. The proliferation of HUVEC stimulated by FGF1 is markedly decreased after Ferulic acid treatment ranging from 5 to 40 μM for 24 h. Ferulic acid does not exert significant cell viability up to 20 μM, but over 30 μM Ferulic acid exhibits a cytotoxic effect in HUVEC compare to the control. Ferulic acid inhibits FGF1-induced HUVEC migration and invasion in a dose-dependent manner. Ferulic acid markedly suppresses the FGF1-induced phosphorylation of PI3K and Akt. Ferulic acid treatments significantly inhibit MMP-2 and MMP-9 expression stimulated by FGF1^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Treatment with Ferulic acid (FA) potently inhibits FGF1-induced neovascularization. It is found that intragastric administration of Ferulic acid markedly inhibits tumor volume and tumor weight, as compare to the counterparts treated with DMSO. Furthermore, Ferulic acid treatment is well tolerated, and there is no significant difference in weight between the vehicle group and the FA-treated groups^[1]. Ferulic acid (0.01, 0.1, 1 or 10 mg/kg) given by oral route decreases significantly the immobility time in the forced swimming test (FST) and tail suspension test (TST), whereas produces no effect in the open-field test. Results demonstrate that the administration of Ferulic acid (0.001 mg/kg, p.o.) boosts the antidepressant-like effect of Fluoxetine (HY-B0102) (5 mg/kg, p.o.) in the TST^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

194.19

Formula

C₁₀H₁₀O₄

CAS No.

1135-24-6

Appearance

Solid

Color

Off-white to yellow

SMILES

O=C(O)/C=C/C1=CC=C(O)C(OC)=C1

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (514.96 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	5.1496 mL	25.7480 mL	51.4960 mL
5 mM	1.0299 mL	5.1496 mL	10.2992 mL
10 mM	0.5150 mL	2.5748 mL	5.1496 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (12.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (12.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (12.87 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.97%

Select Batch:

Data Sheet (277 KB) SDS (394 KB)

COA (245 KB) HNMR (121 KB) RP-HPLC (249 KB)

Handling Instructions (2659 KB)

References

[1]. Yang GW, et al. Ferulic Acid Exerts Anti-Angiogenic and Anti-Tumor Activity by Targeting Fibroblast Growth Factor Receptor 1-Mediated Angiogenesis. Int J Mol Sci. 2015 Oct 12;16(10):24011-31. [Content Brief]

[2]. Zeni AL, et al. Ferulic acid exerts antidepressant-like effect in the tail suspension test in mice: evidence for the involvement of the serotonergic system. Eur J Pharmacol. 2012 Mar 15;679(1-3):68-74. [Content Brief]

Cell Assay ^[1]	HUVEC (5×10⁴ cells/well) are plated onto a gelatinized 24-well culture plate and cultured in ECGS containing 15% FBS. HUVEC are treated with DMSO (0.1%) or different concentrations of Ferulic acid (FA) (0, 2.5, 5, 10, 20, 30, 40 μM) for 24 h. Cell viability is determined by the MTT assay. After 4 h of incubation, the absorbance is measured at 450 nm with a microplate reader. The results are calculated from six replicates of each experiment. Three independent experiments are performed^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[2]	Male Swiss mice (30 to 40 g) are maintained at 21 to 23°C with free access to water and food, under a 12:12 h light/dark cycle (lights on at 07:00 h). All manipulations are carried out between, 9:00 and 16:00 h, with each animal used only once. In order to investigate the antidepressant-like effect of Ferulic acid, Ferulic acid is administered at a dose range of 0.001 to 10 mg/kg, by oral route (p.o.) 60 min before the forced swimming test (FST), tail suspension test (TST) or open-field test. The control animals receive appropriate vehicle^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Yang GW, et al. Ferulic Acid Exerts Anti-Angiogenic and Anti-Tumor Activity by Targeting Fibroblast Growth Factor Receptor 1-Mediated Angiogenesis. Int J Mol Sci. 2015 Oct 12;16(10):24011-31. [Content Brief] [2]. Zeni AL, et al. Ferulic acid exerts antidepressant-like effect in the tail suspension test in mice: evidence for the involvement of the serotonergic system. Eur J Pharmacol. 2012 Mar 15;679(1-3):68-74. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	5.1496 mL	25.7480 mL	51.4960 mL	128.7399 mL
	5 mM	1.0299 mL	5.1496 mL	10.2992 mL	25.7480 mL
	10 mM	0.5150 mL	2.5748 mL	5.1496 mL	12.8740 mL
	15 mM	0.3433 mL	1.7165 mL	3.4331 mL	8.5827 mL
	20 mM	0.2575 mL	1.2874 mL	2.5748 mL	6.4370 mL
	25 mM	0.2060 mL	1.0299 mL	2.0598 mL	5.1496 mL
	30 mM	0.1717 mL	0.8583 mL	1.7165 mL	4.2913 mL
	40 mM	0.1287 mL	0.6437 mL	1.2874 mL	3.2185 mL
	50 mM	0.1030 mL	0.5150 mL	1.0299 mL	2.5748 mL
	60 mM	0.0858 mL	0.4291 mL	0.8583 mL	2.1457 mL
	80 mM	0.0644 mL	0.3218 mL	0.6437 mL	1.6092 mL
	100 mM	0.0515 mL	0.2575 mL	0.5150 mL	1.2874 mL

Ferulic acid Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Ferulic acid1135-24-6Coniferic acidFGFREndogenous MetaboliteFibroblast growth factor receptorInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Ferulic acid (Synonyms: Coniferic acid)

Customer Review

Other Forms of Ferulic acid:

Ferulic acid Related Antibodies

16 Publications Citing Use of MCE Ferulic acid

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Endogenous Metabolite Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Ferulic acid Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Ferulic acid Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report